Results 1 to 10 of about 468,353 (119)
Emerging frontiers in the mitochondrial regulation of dendritic cell biology [PDF]
Redox BiologyDendritic Cells are central players of our immune system, linking innate sensing to adaptive immunity through antigen presentation and T cell priming. Beyond transcriptional and cytokine-based regulation, mitochondria are emerging as potential regulators
B. Chen, J.U. Mayer
doaj +2 more sources
Frontiers in Immunology, 2022 Antibodies targeting the activation marker CD83 can achieve immune suppression by targeting antigen-presenting mature dendritic cells (DC). This study investigated the immunosuppressive mechanisms of anti-CD83 antibody treatment in mice and tested its ...
Pablo A. Silveira +15 more
doaj +1 more source
Flt3L therapy increases the abundance of Treg-promoting CCR7+ cDCs in preclinical cancer models
Frontiers in Immunology, 2023 Conventional dendritic cells (cDCs) are at the forefront of activating the immune system to mount an anti-tumor immune response. Flt3L is a cytokine required for DC development that can increase DC abundance in the tumor when administered therapeutically.
Emile J. Clappaert +25 more
doaj +1 more source
Targeting CD83 in mantle cell lymphoma with anti‐human CD83 antibody
Clinical & Translational Immunology, 2020 Objectives Effective antibody–drug conjugates (ADCs) provide potent targeted cancer therapies. CD83 is expressed on activated immune cells including B cells and is a therapeutic target for Hodgkin lymphoma.
Ziduo Li +11 more
doaj +1 more source
Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy
Pharmaceutics, 2020 The onset of checkpoint inhibition revolutionized the treatment of cancer. However, studies from the last decade suggested that the sole enhancement of T cell functionality might not suffice to fight malignancies in all individuals. Dendritic cells (DCs)
Lukas Amon +4 more
doaj +1 more source
Neoplasia: An International Journal for Oncology Research, 2005 Dendritic cells (DC) have been implicated in the defective function of the immune system during cancer progression. We have demonstrated that patients with cancer have fewer myeloid (CD11c+) and plasmacytoid (CD123hi) DC and a concurrent accumulation of ...
Alberto Pinzon-Charry +5 more
doaj +1 more source
CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation
Molecular Oncology, 2019 Antibody‐based therapy in acute myeloid leukemia (AML) has been marred by significant hematologic toxicity due to targeting of both hematopoietic stem and progenitor cells (HSPCs).
Edward Abadir +14 more
doaj +1 more source
CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential
Frontiers in Immunology, 2019 CD83 is a member of the immunoglobulin (Ig) superfamily and is expressed in membrane bound or soluble forms. Membrane CD83 (mCD83) can be detected on a variety of activated immune cells, although it is most highly and stably expressed by mature dendritic
Ziduo Li +13 more
doaj +1 more source
Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
Frontiers in Immunology, 2021 Tumors evade the immune system though a myriad of mechanisms. Using checkpoint inhibitors to help reprime T cells to recognize tumor has had great success in malignancies including melanoma, lung, and renal cell carcinoma.
Sarah I. M. Sutherland +10 more
doaj +1 more source
CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma
Haematologica, 2018 Chemotherapy and hematopoietic stem cell transplantation are effective treatments for most Hodgkin lymphoma patients, however there remains a need for better tumor-specific target therapy in Hodgkin lymphoma patients with refractory or relapsed disease ...
Ziduo Li +21 more
doaj +1 more source